FDA Clearance Tracker · P810025-S037
Amvisc and Amvisc Plus Ophthalmic Viscosurgical Device (OVD)
Last checked: Nov 20, 2026Latest source record: Jun 28, 2017 (this decision)Source: openFDAMethods & limitations
Decided
Jun 28, 2017
Approved
Time to decision
309 days
Received Aug 23, 2016. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA supplement
Normal 180 Day Track No User Fee
Device class
Class III
The decision
- FDA number
- P810025-S037
- Device name
- Amvisc and Amvisc Plus Ophthalmic Viscosurgical Device (OVD)
- Applicant
- Bausch & Lomb, Inc.
- Applicant location
- Irvine, CA
- Received
- Aug 23, 2016
- Decided
- Jun 28, 2017
- Decision
- Approved
- Supplement type
- Normal 180 Day Track No User Fee
- Reason for supplement
- Location Change - Manufacturer/Sterilizer/Packager/Supplier
- Original approval
- P810025
Device type
- Device type
- AID, SURGICAL, VISCOELASTIC (LZP)
- Device class
- Class III
- Regulation
- 21 CFR 886.4275
- Specialty
- Ophthalmology
FDA's approval statement
As written in FDA's record.
Approved GMP
Source documents
Other decisions for Bausch & Lomb, Inc.
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
- Bausch + Lomb Multifocal for Astigmatism (kalifilcon A) One-Day Soft (hydrophilic) Contact Lens510(k)
K262941 · Decided Oct 16, 2026 · 56 days after receipt
Device type: Lenses, Soft Contact, Daily Wear (LPL) · Ophthalmology
5 more FDA decisions with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.